Clinical managers face a growing need to communicate the value of what they do in terms that can be interpreted by nonclinical financial managers. We have sought to link the evidence basis of current guidelines to variables that will demonstrate in more financial terms the very real benefit of treating diseases aggressively. We have developed an approach using the medical literature that is designed to describe clinical initiatives in more concrete terms as desired by senior management. This becomes specifically critical during budget time and when justification for various clinical programs is needed. The approach uses medical research from the peer-reviewed literature to estimate the economic impact of various initiatives and then combines the analysis with an organization's actual data to impute potential benefit. A sample grid for developing the analysis is attached. A comprehensive bibliography that will assist others with similar endeavors has been included. Although not as rigorous as formal methods, actuarial analyses, or health services research activities, it presents a beginning framework around which an organization can create operational estimates of initiative effectiveness.
Blue Cross Blue Shield Association. Medical Cost Reference Guide. Revised June 2003. Chicago, IL: Blue Cross Blue Shield Association; 2003.
2.
AAHP. National Health Care costs jump 8.7% in 2001. Research Highlights. January 2003;1-4.
3.
Fetterolf D. Commentary: presenting the value of medical quality to nonclinical senior management and boards of directors. Am J Med Qual. 2003;18(1):10-14.
4.
Clancy C, Kamerow D. Evidence-based medicine meets cost-effectiveness analysis. JAMA. 1996;276(4):329-330.
5.
Eisenbert JM. Evidence-based medicine. Expert Voices. January 2001;1-2.
6.
Eisenberg J. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989;262(20):2879-2886.
7.
Stone RE. Outcomes-driven health care delivery: when better health does not equal higher costs. Washington, DC: Atlantic Information Services; 2002.
8.
NCQA. The business case for health care quality. Available at: www.ncqa.org. Accessed July 23, 2003.
9.
Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40-49 years of age. Ann Intern Med1997;127:955-965.
10.
Nichol KL, Wuorenma J, von Sternberg T, et al.Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 1998;158:1769-1776.
11.
Nichol K, Lind A, Margolis K, et al.The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med. 1995;333:889-893.
12.
Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc. 2002;94(8 suppl):7S-15S.
13.
Kronz JD, Kroll MH. Microalbuminuria testing for the prevention of renal disease in diabetes mellitus: a strategy to save lives and money. The authoritative source for the clinical laboratorian. Available at: www.aacc.org/cln/features/resultsdetailArticlelD=49. Accessed June 5, 2003.
14.
Perkins BA, Ficociello LH, Silva KH, et al.Regression of Micro-albuminuria in type 1 diabetes. N Engl J Med. 2003;348(23): 2285-2293.
15.
Hubbell W. Combining economic value added and activity based management. J Cost Manage. 1996;10:18-29.
16.
Doxtator R, Rodriquez M. Evaluating costs, benefits, and return on investment for disease management programs. Dis Manag. 1998;1(4):185-192.
17.
Gold M, Siegel J, Russel L, et al.Cost effectiveness in health and medicine. Report of the U.S. Public Health Service Panel on Cost Effectiveness in Health and Medicine. Oxford, UK: Oxford University Press; 1996.
18.
Plocher D, Brody R. Disease mangement and return on investment. In Kongstuedt P, Plocher D, eds. Best Practices in Medical Management. Gaithersburg, MD: Aspen; 1998:397-406.
19.
Aldana S. Financial impact of health promotion programs: a comprehensive review of the literature. Am J Health Promot. 2001;15(5):296-320.
20.
American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(1):s33-s50.
21.
Anderson D, Serxner S, Gold D. Conceptual framework, critical questions, and practical challenges in conduction research on the financial impact of worksite health promotion. Am J Health Promot. 2001; 15(5):281-288.
22.
Anderson D, Whitmer W, Goetzel R, et al.The relationship between modifiable health risks and group-level health care expenditures. Am J Health Promot. 2000;15(1):45-52.
23.
Anderson G, Reinhardt U, Hussey P, et al.It's the prices stupid: why the United States is so different from other countries. Health Aff2003;22(3):89-105.
24.
Armour B, Pitts M, Maclean R, et al.The effect of explicit financial incentives on physician behavior. Arch Intern Med. 2001;161:1261-1266.
25.
Blue Cross Blue Shield Association. What's Behind the Rise: A Comprehensive Analysis of Healthcare Costs. Executive Summary. Chicago, IL: Blue Cross Blue Shield Association. 2002.
26.
Bradley E, Holmboe E, Mattera J, et al.A qualitative study of increasing beta blocker use after myocardial infarction. Why do some hospitals succeed. JAMA. 2001;285(20):2604-2611.
27.
Breslow L. Why health promotion lags knowledge about healthful behavior. Am J Health Promot. 2001;15(5):388-390.
28.
Bridges C, Thompson W, Meltzer M, et al.Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284(13):1655-1663.
29.
CDC-Division of Sexually Transmitted Diseases. Chlamydia in the United States. Washington, DC: CDC-National Center for HIV, STD, and TB Prevention, Division of STD Prevention; 2001.
30.
Centers for Disease Control and Prevention. Sexually Transmitted Diseases Surveillance 2000 Supplement, Clamydia Prevalence Monitoring Project. Washington, DC: Department of Health and Human Services, Centers for Disease Control and Prevention; 2001.
31.
Clinical Evidence Concise. July 2002. London: BMJ Publishing Group.
32.
Cohen G, Nettleman M. Economic impact of influenza vaccination in preschool children. Pediatrics. 2000;106(5):973-977.
33.
Coyne MJ. No Toyotas in health care: why medical care has not evolved to meet patients needs. Health Aff. 2001;20(6):44-56.
34.
Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276(17):1409-1415.
35.
Edington D. Emerging research: a view from one research center. Am J Health Promot. 2001;15(5):341-349.
36.
Editorial. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132-1133.
37.
Eriksson H. Heart failure: a growing health problem. J Intern Med. 1995;237:135-141.
38.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
39.
Gibbons RJ, Abrams J, et al.ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. Circulation. 2003;107:149-158.
40.
Goetzel R. The financial impact of health promotion and disease prevention programs-why is it so hard to prove value?Am J Health Promot. 2001;15(5):277-278.
41.
Goetzel R. A corporate perspective: reflections from the economic buyer of health promotion programs. Am J Health Promot. 2001;15(5): 357-377.
42.
Golaszewki T. Shining lights: studies that have most influenced the understanding of health promotion's financial impact. Am J Health Promot. 2001;15(5):332-340.
43.
Gordon C, Lapin P. A government perspective: if there is so much proof, why is medicare not rapidly adopting health promotion and disease prevention programs?Am J Health Promot. 2001;15(5):383-387.
44.
Grundy S, Benjamin I, Burke G, et al.Diabetes and cardiovascular disease. A statement for healthcare professionals from the American heart association. Circulation. 1999;100:1134-1146.
45.
Harris J, Holman P, Carande-Kulis V. Financial impact of health promotion: we need to know much more, but we know enough to act. Am J Health Promot. 2001;15(5):378-382.
46.
Harris J, Schauffier H, Mislstein A, et al.Expanding health insurance coverage for smoking cessation treatments: experience of the Pacific business group on health. Am J Health Promot. 2001;15(5): 350-356.
47.
Haynes G, Dunnagan T. Comparing changes in health risk factors and medical costs over time. Am J Health Promot. 2002;17(2):112-121.
48.
Howell M, Rene MA, et al.Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. Sex Transm Dis. 1999;26(9):519-526.
49.
Hunt S, Baker D, Chin M, et al.ACCIAHA Practice Guidelines for Treating Patients with Congestive Heart Failure. 2002.
50.
Javitt JC, Aiello L, Chiang Y, et al.Preventative eye care in people with diabetes is cost-saving to the federal government. Diabetes Care. 1994;17(8):909-917.
51.
Johnson A. Measuring DM's net effect is harder than you might think. Available at: http://www.managedcaremag.com/archives/0306/0306.dmnmilliman.htm. Accessed June 1, 2003.
52.
Kerzner R, Rich M. Does multidisciplinary management of chronic heart failure improve clinical outcomes?JCOM. 2002;8(2):41-49.
53.
Koplan JP. Diabetes: Disabling, Deadly, and on the Rise. 2003.
54.
Lai LL, Sorkin AL. Cost benefit analysis of pharmaceutical care in a medicaid population-from a budgetary perspective. J Manag Care Pharm. 1998;4:303-308.
55.
Lee P, Matchar D, Clements D, et al.Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med. 2002;137:225-231.
56.
Levinsky NG, et al.Influence of age on medicare expenditures and medical care in the last year of life. JAMA. 2001;286(11):1349-1355.
57.
Lieu TA, Cochi SL, et al.Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271(5):375-381.
58.
Lozano P, Fishman P. Health care utilization and cost among children with asthma who were enrolled in a health maintenance organization. Pediatrics. 1997;99(6).
59.
Margolis HS, Coleman PJ, et al.Prevention of Hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274(15):1201-1208.
60.
Max W. The financial impact of smoking on health related costs: a review of the literature. Am J Health Promot. 2001;15(5):321-331.
61.
Meltzer D, Egleston B, Stoffel D, et al.Effect of future costs on cost effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care. 2000;38(6):679-685.
62.
Meltzer D, Egleston B, Stoffel D, et al.Effect of future costs on cost effectiveness of medical interventions among young adults. Med Care. 2000;38(6):679-685.
63.
Millenson M. America's Health Care Challenge: Rising Costs. A Report Commissioned by the American Association of Health Plans. Washington, DC: American Association of Health Plans; 2002.
64.
Morton V, Torgerson D. Effect of regression to the mean on decision making in health care. BMJ2003;326:1083-1084.
65.
NAEPP/NIH. NAEPP Expert Panel Report Guidelines for the Diagnosis and Management of Asthma-Update on Selected Topics 2002. Bethesda, MD: NIH; 2002.
66.
National Institutes of Health/National Heart, Lung, and Blood Institute. Expert Panel Report 2-Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NIH; 2002.
67.
Neuner J, Hamel M, Phillips R, et al.Diagnosis and management of adults with pharyngitis. A cost-effectiveness analysis. Ann Intern Med. 2003;139(2):113-122.
68.
Nichol KL, Nordin J, Mullooly J, et al.Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14).
69.
Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care. 2002;25(3):482-486.
70.
O'Brien JA, Shomphe LA, Kavanagh P, et al.Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 1998;21(7):1122-1128.
71.
Ozminkowski R, Goetzel R. Getting closer to the truth: overcoming research challenges when estimating the financial impact of worksite health promotion programs. Am J Health Promot. 2001;15(5):289-295.
72.
Ozminkowski R, Goetzel R, Smith M, et al.The impact of citibank, NA, health management on changes in employee health risks over time. J Occup Environ Med. 2000;42(5):502-511.
73.
Phillips KA, Shlipak MG. Health and economic benefits of increased [beta]-blocker use following myocardial infarction. JAMA. 2000; 284(21):2748-2754.
74.
Pierce Gardner MD. A need to update and revise the pneumococcal vaccine recommendations for adults. Ann Intern Med. 2003;138(12): 999-1000.
75.
Pignone MP, Gaynes BN. Screening for depression in adults: a summary of the evidence. Ann Intern Med. 2002;136(10):765-776.
76.
Polanczyk CA, Rohde LE. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med. 2000;160(3):325-332.
77.
Pronk N, Goodman M, O'Connor P, et al.Relationships between modifiable health risks and short term health care changes. JAMA. 1999; 282(23):2235-2239.
78.
Sacks FM, Pfeffer MA, Maye L, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001-1009.
79.
Saywell R, Champion V, Zollinger T, et al.The cost effectiveness of 5 interventions to increase mammography adherence in a managed care population. Am J Manag Care. 2003;9:33-44.
80.
Sisk JE, Whang W, Butler JC, et al.Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960-968.
81.
Smith S, Blair S, Bonow R, et al.AHIA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Coronary Artery Disease: 2001 Update. Consensus Panel Guide to Comprehensive Risk Reduction for Patients with Coronary and Other Vascular Disease. Dallas, TX: American Heart Association; 2001.
82.
Stewart W, Ricci J, Chee E, et al.Cost of lost productive work time among US workers with depression. JAMA. 2003;289(23):3135-3144.
83.
Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Afft2002;21(2):245-253.
84.
The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type I diabetes mellitus and microalbuminuria receive ACE inhibitors?Ann Intern Med. 2001;134:370-379.
85.
Tucker L, Clegg A. Differences in health care costs and utilization among adults with selected lifestyle-related risk factors. Am J Health Promot. 2002;16(4):225-233.
86.
US Department of Health and Human Services. MMWR-Recommendations and Reports, Immunization of Adolescents. Bethesda, MD: DHS-Center for Disease Control and Prevention; 1996.
87.
US Preventive Services Task Force. Recommendations and Rationale-Screening for Depression. Available at: www.ahrq.gov/clinic/3rduspstfldepression/depression.htm. Accessed May 29, 2003.
88.
Villagra V. Cost Effectiveness of Disease Management Programs-Summary of Research Findings. Washington, DC: Disease Management Association of America; 2003.
89.
Warner KE, Smith RJ, Smith DG, et al.Health and economic implications of a work-site smoking-cessation program: a simulation analysis. J Occup Enuiron Med. 1996;38(10):981-982.
90.
Warner K, Smith R, Smith D, et al.Health and economic implications of a work-site smoking-cessation program: a simulation. J Occup Environ Med. 1996;38(10):981-992.
91.
Wasserman J, Whitmer R, Bazzarre T, et al.Gender-specific effects of modifiable health risk factors on coronary heart disease and related expenditures. J Occup Environ Med. 2000;42:1060-1069.
92.
Wayne K. Decision Support for Key Chronic Conditions: Improving Outcomes of Depression in Primary Care. Boston, MA: The Institute for Healthcare Improvement; 2003.
